Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China flag China · Delayed Price · Currency is CNY
15.11
+0.13 (0.87%)
Apr 28, 2026, 3:00 PM CST

SHA:600535 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
628.351,4362,9944,4513,1192,304
Short-Term Investments
-1,404----
Trading Asset Securities
1,8341,394524.72300.711,1251,487
Cash & Short-Term Investments
2,4624,2343,5184,7514,2443,791
Cash Growth
-15.96%20.34%-25.95%11.95%11.95%78.94%
Accounts Receivable
2,6552,4181,9662,1313,3483,796
Other Receivables
39.7139.9623.0611.498.989.47
Receivables
2,6942,4581,9892,1423,3573,805
Inventory
1,4431,4271,7121,7481,5321,548
Other Current Assets
2,024111.591.7291.43127.08105
Total Current Assets
8,6248,2307,3118,7339,2609,249
Property, Plant & Equipment
3,4883,5463,6483,7693,8834,088
Long-Term Investments
1,3701,3461,8212,0541,5111,229
Goodwill
---15.8815.88167.08
Other Intangible Assets
776.98794.39604.17573.64459.43474.54
Long-Term Deferred Tax Assets
66.6567.0553.175088.2960.79
Long-Term Deferred Charges
1,3431,3331,4661,4761,1571,193
Other Long-Term Assets
24.1122.6672.5443.14102.0879.68
Total Assets
15,69415,34014,97616,71416,47716,542
Accounts Payable
472.1376.9606.81572.73887.77728.58
Accrued Expenses
239.83537.57171.05178.38242.79213.15
Short-Term Debt
829.411,116699.54814.63201.77188.79
Current Portion of Long-Term Debt
77.994.96586.83462.74475.21343.33
Current Portion of Leases
-49.747.8458.5453.9855.67
Current Income Taxes Payable
246.81110.9157.7818.0484.62108.09
Current Unearned Revenue
50.0249.8869.8591.6292.3568.33
Other Current Liabilities
404.9462.39109.98172.88108.72149.12
Total Current Liabilities
2,3212,3082,3502,3702,1471,855
Long-Term Debt
201.57216.87253.761,4141,3761,034
Long-Term Leases
40.4251.1967.9781.5275.3181.63
Long-Term Unearned Revenue
188.19189.95193.29159.02177.79214.57
Long-Term Deferred Tax Liabilities
36.6826.020.40.1122.8742.18
Total Liabilities
2,7882,7922,8654,0243,7993,228
Common Stock
1,4941,4941,4941,5001,5001,513
Additional Paid-In Capital
482.35482.39458.96958.081,4571,530
Retained Earnings
10,76110,3919,8989,9299,35110,222
Treasury Stock
----105.98-105.98-251.29
Comprehensive Income & Other
30.8337.2452.2288211.58-32.19
Total Common Equity
12,76812,40411,90312,36812,41212,981
Minority Interest
137.77143.49207.86321.59265.12332.56
Shareholders' Equity
12,90612,54812,11112,69012,67813,314
Total Liabilities & Equity
15,69415,34014,97616,71416,47716,542
Total Debt
1,1491,4381,6562,8312,1821,704
Net Cash (Debt)
1,3132,7951,8621,9202,0622,088
Net Cash Growth
-21.70%50.10%-2.99%-6.89%-1.23%-
Net Cash Per Share
0.881.871.251.291.401.39
Filing Date Shares Outstanding
1,4941,4941,4941,4941,4941,499
Total Common Shares Outstanding
1,4941,4941,4941,4941,4941,499
Working Capital
6,3035,9224,9616,3637,1137,394
Book Value Per Share
8.558.307.978.288.318.66
Tangible Book Value
11,99111,61011,29911,77911,93712,340
Tangible Book Value Per Share
8.037.777.567.887.998.23
Buildings
-3,5293,5173,5053,4903,398
Machinery
-3,8033,7633,6253,4723,340
Construction In Progress
-322.42221.76153.87102.96167.85
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.